Close
Close
Finance News

Soligenix to Present at the 2017 Biotech and Money Showcase Conference

2.5
2.5 from 2 votes
Tuesday, November 14, 2017

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will deliver a corporate presentation at the 2017 Biotech & Money Investival Showcase in London, England, Tuesday, November 14, at 1:30 PM GMT. The event will take place at The Waldorf Hilton Hotel.

To access an audio webcast of the Soligenix corporate presentation, please click here.

Dr. Schaber will also be participating in the Jeffries 2017 London Healthcare Conference on November 15-16, 2017, co-located at The Waldorf Hilton Hotel.

For more information about the 2017 Biotech & Money Investival Showcase, please refer to the conference website here.

About Soligenix, Inc.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our BioTherapeutics business segment is developing SGX301 as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn's disease (SGX203) and acute radiation enteritis (SGX201).

Our Vaccines/BioDefense business segment includes active development programs for RiVax®, our ricin toxin vaccine candidate, OrbeShield®, our GI acute radiation syndrome therapeutic candidate and SGX943, our therapeutic candidate for antibiotic resistant and emerging infectious disease. The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA).

For further information regarding Soligenix, Inc., please visit the Company's website at www.soligenix.com.

Source: Soligenix, Inc.
2.5
2.5 from 2 votes
Free Newsletter
Videos
by Scott Harwood
17 views
by Abidemi Uruejoma
17 views
by Scott Harwood
17 views